Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

To TDM or not to TDM in lupus nephritis patients treated with MMF?

van Gelder T, Berden JH, Berger SP.

Nephrol Dial Transplant. 2015 Apr;30(4):560-4. doi: 10.1093/ndt/gfu184. Review.

PMID:
24811231
2.

Therapeutic Drug Monitoring of Mycophenolic Acid in Lupus Nephritis: A Review of Current Literature.

Łuszczyńska P, Pawiński T.

Ther Drug Monit. 2015 Dec;37(6):711-7. doi: 10.1097/FTD.0000000000000223. Review.

PMID:
26034895
3.

Concentration-controlled treatment of lupus nephritis with mycophenolate mofetil.

Daleboudt GM, Reinders ME, den Hartigh J, Huizinga TW, Rabelink AJ, de Fijter JW, Berger SP.

Lupus. 2013 Feb;22(2):171-9. doi: 10.1177/0961203312469261.

PMID:
23257398
4.

Therapeutic drug monitoring of mycophenolate mofetil for the treatment of severely active lupus nephritis.

Kittanamongkolchai W, Rukrung C, Supasiri T, Lertjirachai I, Somparn P, Chariyavilaskul P, Avihingsanon Y.

Lupus. 2013 Jun;22(7):727-32. doi: 10.1177/0961203313486949.

PMID:
23651860
5.

Optimizing the dose of mycophenolate mofetil for the maintenance treatment of lupus nephritis by therapeutic drug monitoring.

Zabotti A, Baraldo M, Quartuccio L, Sacco S, De Marchi G, De Vita S.

Clin Rheumatol. 2015 Jan;34(1):171-4. doi: 10.1007/s10067-014-2786-9.

PMID:
25249327
6.

Exposure-effect relationship of mycophenolic acid and prednisolone in adult patients with lupus nephritis.

Abd Rahman AN, Tett SE, Abdul Gafor HA, McWhinney BC, Staatz CE.

Br J Clin Pharmacol. 2015 Nov;80(5):1064-75. doi: 10.1111/bcp.12678.

7.

Pharmacokinetics of concentration-controlled mycophenolate mofetil in proliferative lupus nephritis: an observational cohort study.

Alexander S, Fleming DH, Mathew BS, Varughese S, Jeyaseelan V, Tamilarasi V, Jacob CK, John GT.

Ther Drug Monit. 2014 Aug;36(4):423-32. doi: 10.1097/FTD.0000000000000031.

PMID:
25014074
8.

Pharmacokinetics of mycophenolic acid in severe lupus nephritis.

Lertdumrongluk P, Somparn P, Kittanamongkolchai W, Traitanon O, Vadcharavivad S, Avihingsanon Y.

Kidney Int. 2010 Aug;78(4):389-95. doi: 10.1038/ki.2010.170.

9.

Use of Glucuronidated Mycophenolic Acid Levels for Therapeutic Monitoring in Pediatric Lupus Nephritis Patients.

Hui-Yuen JS, Tran T, Taylor J, Truong K, Li X, Bermudez LM, Starr AJ, Eichenfield AH, Imundo LF, Askanase AD.

J Clin Rheumatol. 2016 Mar;22(2):75-9. doi: 10.1097/RHU.0000000000000357.

PMID:
26906299
11.

Pediatric aspects of therapeutic drug monitoring of mycophenolic acid in renal transplantation.

Tönshoff B, David-Neto E, Ettenger R, Filler G, van Gelder T, Goebel J, Kuypers DR, Tsai E, Vinks AA, Weber LT, Zimmerhackl LB.

Transplant Rev (Orlando). 2011 Apr;25(2):78-89. doi: 10.1016/j.trre.2011.01.001. Review.

PMID:
21454065
12.

Therapeutic drug monitoring of mycophenolic acid: a potential treatment for lupus nephritis.

Pawinski T.

Kidney Int. 2010 Aug;78(4):335-6. doi: 10.1038/ki.2010.181.

13.

How accurate and precise are limited sampling strategies in estimating exposure to mycophenolic acid in people with autoimmune disease?

Abd Rahman AN, Tett SE, Staatz CE.

Clin Pharmacokinet. 2014 Mar;53(3):227-45. doi: 10.1007/s40262-013-0124-z. Review.

PMID:
24327238
14.

Therapeutic drug monitoring of mycophenolic acid: does it improve patient outcome?

de Winter BC, Mathôt RA, van Hest RM, van Gelder T.

Expert Opin Drug Metab Toxicol. 2007 Apr;3(2):251-61. Review.

PMID:
17428154
15.

Therapeutic drug monitoring for mycophenolic acid in patients with autoimmune diseases.

de Winter BC, van Gelder T.

Nephrol Dial Transplant. 2008 Nov;23(11):3386-8. doi: 10.1093/ndt/gfn497. No abstract available.

PMID:
18780901
16.
17.

Mycophenolic acid: measurement and relationship to pharmacologic effects.

Shaw LM, Nowak I.

Ther Drug Monit. 1995 Dec;17(6):685-9. Review.

PMID:
8588242
18.

Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation.

Mino Y, Naito T, Matsushita T, Otsuka A, Ushiyama T, Ozono S, Hishida A, Kagawa Y, Kawakami J.

Ther Drug Monit. 2008 Dec;30(6):656-61. doi: 10.1097/FTD.0b013e31818b8244.

PMID:
18978521
19.

Maximum a posteriori Bayesian estimation of mycophenolic Acid area under the concentration-time curve: is this clinically useful for dosage prediction yet?

Staatz CE, Tett SE.

Clin Pharmacokinet. 2011 Dec 1;50(12):759-72. doi: 10.2165/11596380-000000000-00000. Review.

PMID:
22087863
20.

The compelling case for therapeutic drug monitoring of mycophenolate mofetil therapy.

Filler G, Alvarez-Elías AC, McIntyre C, Medeiros M.

Pediatr Nephrol. 2017 Jan;32(1):21-29. Review.

PMID:
26921212

Supplemental Content

Support Center